Delving into the Latest Updates on HRS-2129 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

HRS-2129

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesOther DiseasesImmune System Diseases+ [2]

Active Indication

Pain, PostoperativeAcute PainDiabetic peripheral neuropathic pain+ [2]

Inactive Indication-

Originator Organization

Shandong Suncadia Medicine Co., Ltd.

Active Organization

Shanghai Hengrui Pharmaceutical Co., Ltd.Shandong Suncadia Medicine Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Login to view timeline

Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.

Start Date10 Mar 2026

Sponsor / Collaborator

Shandong Suncadia Medicine Co., Ltd.

NCT07185594

/ RecruitingPhase 2/3

A Phase Ⅱ/Ⅲ Study to Evaluate the Efficacy and Safety of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery

This is a phase II/III, multi-center, randomized, double-blind, comparator-controlled study to evaluate the efficacy and safety of HRS-2129 for postoperative pain management in abdominal surgery.

Start Date24 Oct 2025

Sponsor / Collaborator

Shandong Suncadia Medicine Co., Ltd.

100 Clinical Results associated with HRS-2129

Login to view more data

100 Translational Medicine associated with HRS-2129

Login to view more data

100 Patents (Medical) associated with HRS-2129

Login to view more data

100 Deals associated with HRS-2129

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain, Postoperative	Phase 3	China	Shandong Suncadia Medicine Co., Ltd.	24 Oct 2025
Acute Pain	Phase 3	China	Shandong Suncadia Medicine Co., Ltd.	23 Oct 2025
Acute Pain	Phase 3	China	Shanghai Hengrui Pharmaceutical Co., Ltd.	23 Oct 2025
Diabetic peripheral neuropathic pain	Phase 1	China	Shanghai Hengrui Pharmaceutical Co., Ltd.	16 Mar 2026
Diabetic peripheral neuropathic pain	Phase 1	China	Shandong Suncadia Medicine Co., Ltd.	16 Mar 2026
Osteoarthritis, Knee	Phase 1	China	Shanghai Hengrui Pharmaceutical Co., Ltd.	03 Mar 2026
Osteoarthritis, Knee	Phase 1	China	Shandong Suncadia Medicine Co., Ltd.	03 Mar 2026
Pain	Phase 1	China	-	15 Nov 2024